Clinical trials targeting the IFN-I pathway (either IFN-I-producing cells, soluble IFN-I, or the IFN-I receptor) in patients with SLE, however, have shown efficacy only in a subset of patients expressing the IFN signature.16 The gene discussed is IFNA1; the disease is systemic lupus erythematosus.